0086-199 9282 1268 info@amulyn.com

Snake-Venom-Like Tripeptide

AMULYN synthetic snake-venom-like tripeptide for eye creams, eye masks and anti-wrinkle skincare formulations. Explore peptide mechanism, test data and sourcing.

HOT:

AMULYN Cosmetic Peptide Ingredient

Snake-Venom-Like Tripeptide for Instant Wrinkle-Care Formulations

A synthetic cosmetic peptide ingredient positioned for eye masks, eye creams and anti-wrinkle skincare development. The supplied product brochure describes a high-purity peptide powder and a liquid solution format inspired by the action mechanism of Waglerin-1.

CAS 823202-99-9Identifier shown in the supplied brochure
375.5 g/molMolecular weight shown in the product profile
2-8°C storageLight-protected, dry and sealed storage
Powder and liquid formatsConfirm commercial format and current TDS
Snake-venom-like tripeptide cosmetic ingredient for peptide formulation development

Ingredient profile

A synthetic peptide concept for targeted wrinkle-care products

The supplied brochure describes this ingredient as a synthetic tripeptide that models the action mechanism of Waglerin-1 from Temple Viper venom. It is synthesized from amino acids and is not obtained by extracting snake venom.

The product profile positions it for immediate wrinkle-care concepts, especially functional eye masks, eye creams and anti-wrinkle skincare products. Final product claims must be reviewed against the finished formulation, substantiation package and destination-market requirements.

Synthetic amino-acid peptide
Eye-care application focus
High-purity powder format stated
Liquid solution format available

Visual library

Show the peptide, formulation process and finished-product context

Replace the image placeholders with approved product, laboratory, structure, packaging and application images. Use owned or licensed visuals only.

Recommended image set: peptide powder, chemical structure, mechanism diagram, transparent solution, laboratory testing, eye cream, eye mask, finished packaging, quality-control area and shipping carton.

Chemical structure and mechanism diagram for snake-venom-like tripeptide

Mechanism concept

Designed to model a neurotransmitter-pathway mechanism

According to the supplied brochure, the peptide is designed to interact with the ε subunit of the postsynaptic nicotinic acetylcholine receptor. The brochure describes the intended sequence as reducing acetylcholine binding, limiting receptor opening and reducing the muscle-contraction signal.

The same source describes the concept as fast-acting, long-lasting and reversible. These statements are product-brochure claims and should be supported with the applicable technical and cosmetic substantiation documents before being used in advertising or on-pack copy.

Action pathway

How the brochure explains the wrinkle-care concept

This section translates the source brochure's diagram into a buyer-friendly sequence. It is not a medical or clinical treatment description.

Signal release

The brochure illustrates acetylcholine release from the presynaptic nerve ending.

Receptor interaction

The peptide is described as interacting with the postsynaptic nicotinic acetylcholine receptor.

Reduced contraction signal

The brochure describes reduced neurotransmitter-driven muscle movement in the target mechanism.

Skin appearance concept

The cosmetic positioning is smoother-looking skin and wrinkle-care support in finished products.

Product applications

Built around eye-care and anti-wrinkle formulation briefs

The supplied brochure lists the following application directions. Confirm suitability in the buyer's own formulation system and destination-market compliance review.

Eye cream formulation using a cosmetic peptide ingredientEye care

Functional eye creams

Use the peptide as an ingredient direction for eye-care formulas developed around wrinkle appearance and skin-smoothing claims.

Functional eye mask cosmetic formulation with peptide ingredientsEye mask

Functional eye masks

The brochure specifically lists functional eye masks as an application direction for the peptide.

Anti-wrinkle skincare formulation containing a cosmetic peptideSkincare

Anti-wrinkle skincare

Suitable for formulation discussions involving anti-wrinkle skincare concepts, subject to finished-product testing and claim review.

Technical profile

Core information shown in the supplied product brochure

Use this summary for initial sourcing discussions. Request the current technical data sheet, specification, COA and regulatory documents before approval.

Item Information Publication note
Product name Snake-Venom-Like Tripeptide / 类蛇毒三肽 English naming follows the supplied brochure concept.
INCI shown Dipeptide Diaminobutyroyl Benzylamide; another brochure section shows Dipeptide Diaminobutyroyl Benzylamide Diacetate Confirm the commercial form and current INCI documentation before final publication.
CAS 823202-99-9 Shown in the product profile; verify against the purchased material's documentation.
Sequence H-β-Ala-Pro-Dab-NH-Bzl As shown in the product profile.
Molecular formula C₁₉H₂₉N₅O₃ As shown in the product profile.
Molecular weight 375.5 g/mol As shown in the product profile.
Powder description High-purity peptide powder No exact powder purity percentage is stated in the supplied brochure.
Liquid solution 2,500 ppm Format-specific information; do not use as the powder concentration.
Liquid solution addition level 1.0-8.0% Listed for the liquid solution; confirm the correct use level for the purchased format.
Storage Protect from light; keep dry and sealed; refrigerate at 2-8°C The brochure states room-temperature transport is possible.
Packaging __PACKAGING_TO_CONFIRM__ The brochure's 1 kg / 5 kg / 10 kg / 25 kg options are general liquid-peptide packaging information, not confirmed for this product.

Important: the supplied brochure uses different INCI forms in different sections. Do not publish a final ingredient declaration until the supplier confirms the exact commercial form.

In-vitro test reference

Elastase inhibition data shown in the brochure

The brochure reports an in-vitro elastase inhibition test. These results are not clinical results and should not be presented as proof of treatment or guaranteed finished-product performance.

38.80%10 ppm sample

Reported elastase inhibition rate in the supplied brochure.

43.38%50 ppm sample

Reported elastase inhibition rate in the supplied brochure.

44.32%250 ppm sample

Reported elastase inhibition rate in the supplied brochure.

Test reference from the brochure: blank control, positive control EGCG, sample and control wells; 50 µL elastase was added except to the blank group, followed by incubation at 37°C for 10 minutes before OD measurement. The positive-control rate shown was 88.47%. Request the original test report and method validation before using these values in a commercial claim.

Formulation support

Start with the correct commercial format

The brochure references both a high-purity powder and a 2,500 ppm liquid solution. The liquid solution is listed at 1.0-8.0% addition. Powder use level, solvent system, compatibility, processing temperature and preservation requirements should be confirmed from the relevant technical documentation.

  • Powder purity__PURITY_TO_CONFIRM__
  • Powder addition level__POWDER_USE_LEVEL_TO_CONFIRM__
  • Liquid concentration2,500 ppm
  • Liquid addition level1.0-8.0%
Cosmetic peptide liquid solution and formulation testing

Responsible product communication

Use cosmetic-ingredient language throughout the page

Publication boundary: The supplied brochure states that the product is for cosmetic raw-material use and not for human consumption or clinical use. The terms “snake-venom-like” and “Waglerin-1” describe the mechanism concept in the brochure; they do not mean the ingredient is snake venom or a medicine. Confirm all INCI, safety, claim, patent and market-registration requirements with the responsible regulatory team before publication.

FAQ

Questions from cosmetic peptide buyers

What is snake-venom-like tripeptide?

It is a synthetic cosmetic peptide ingredient described in the supplied brochure as modelling the action mechanism of Waglerin-1 from Temple Viper venom. It is synthesized from amino acids and is not extracted from snake venom.

What is the INCI name?

The brochure uses both Dipeptide Diaminobutyroyl Benzylamide and Dipeptide Diaminobutyroyl Benzylamide Diacetate in different sections. Confirm the commercial form and current INCI documentation before using one form on a label or regulatory file.

Which products can use this peptide?

The brochure lists functional eye masks, eye creams and anti-wrinkle skincare products. Final suitability and claims should be validated in the finished formulation and destination market.

What is the recommended addition level?

The brochure lists 1.0-8.0% for the 2,500 ppm liquid solution. It does not provide a powder addition level.

How should the product be stored?

Protect it from light, keep it dry and sealed, and refrigerate at 2-8°C. The brochure states that room-temperature transport is possible.

Start a peptide sourcing discussion

Tell us your target format, application and destination market.

For a relevant quotation and technical review, include powder or liquid format, target product, expected use level, trial quantity, packaging requirement, destination market and documentation needs.

Send an Inquiry
Product Recommendation
Download

1208, Building B, Huixin 1BC, No. 1 Zhang Bayi Road, High-tech Zone, Xi'an, Shaanxi, China

0086-199 9282 1268

info@amulyn.com

Linkedin Youtube Facebook Tiwtter TIKTOK

Copyright @ 2024 AMULYN Corp All rights reserved.

Technical Support | Site Map
Message Form

Company *

Name *

E-Mail *

Area Code *

Tel *

Classifly *

Country *

Detailed Description *

Download

Enter Password Or Obtain a Password